IL2RA and acute myeloid leukemia: The poor outcome of CD25+ AML patients has been attributed to the chemoresistant properties of the LSC-like, CD25+ myeloblasts, a fact illustrated on the higher rates of both induction failure2 and relapse.1, 3 By contrast, we observed comparable response rates to azacitidine among CD25-positive and -negative cases, while CD25+ myeloblasts were equally reduced on day 15 in both responding and not responding patients (data not shown).